Flexion Therapeutics Inc (FLXN) has 71 open-market insider trades by 20 insiders since 2014. The most active filer is Michael D. Clayman, CEO & President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| A/s Novo | 10% | — | 3 | $20.6M | 2015-06-22 |
| Samuel D. Colella | Dir10% Owner | — | 7 | $15.5M | 2021-11-19 |
| Barbara N. Lubash | 10% Owner | — | 1 | $10.0M | 2016-06-08 |
| Bradley J. Bolzon Ph.D. | Dir10% | — | 1 | $4.0M | 2014-02-18 |
| Versant Venture Capital III, L.P. | 10% | — | 1 | $4.0M | 2014-02-18 |
| Sofinnova Partners SAS | 10% | — | 2 | $3.2M | 2014-10-29 |
| Rafael Tordjman | Dir10% | — | 1 | $3.0M | 2014-02-18 |
| Neil Bodick | CSO | — | 12 | $2.1M | 2019-10-07 |
| Michael D. Clayman | CEOPres | — | 16 | $1.3M | 2021-11-19 |
| Frederick W. Driscoll | CFO | — | 4 | $772K | 2021-11-19 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Mark S. Levine | General Counsel | Sell | $25K | 2021-07-19 |
| Adam Muzikant | Chief Business Officer | Sell | $12K | 2021-07-19 |
| Kerry Wentworth | Chief Regulatory Officer | Sell | $25K | 2021-07-19 |
| David Arkowitz | CFO | Sell | $16K | 2021-05-10 |
| Melissa Layman | CCO | Sell | $53K | 2021-03-15 |
| Melissa Layman | Chief Commercial Officer | Sell | $33K |
Companies that share insiders with FLXN, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2021-01-28 |
| Christina Willwerth | CSO | Sell | $147K | 2021-01-05 |
| Mark S. Levine | CLO | Sell | $152K | 2021-01-05 |
| Adam Muzikant | Chief Business Officer | Sell | $45K | 2021-01-05 |
| David Arkowitz | CFO | Sell | $135K | 2021-01-05 |
| Mark Stejbach | Director | Buy | $20K | 2020-05-26 |
| Michael D. Clayman | CEO & President | Buy | $100K | 2020-05-26 |
| David Arkowitz | CFO | Sell | $26K | 2020-05-07 |
| Samuel D. Colella | Director & 10% | Buy | $21K | 2019-08-08 |
| Michael D. Clayman | President | Buy | $25K | 2019-08-08 |